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chronic cough: the treatment in patients with 
nasal disease should be tailored to the specific 
otolaryngologic condition. Data from random-
ized, controlled trials of specific therapies for 
nasal disease in patients presenting with chron-
ic cough are lacking, and only uncontrolled ob-
servational data provide support for the efficacy 
of ipratropium bromide, nonspecific antihista-
mines, and decongestants in this patient group.2 
Nonpharmacologic interventions have been shown 
to be effective in treating typical symptoms of 
gastroesophageal reflux disease such as heart-
burn and regurgitation,3 and these approaches 
are mentioned in recent guidelines for the man-
agement of chronic cough.4 We did not empha-
size these maneuvers in our brief review because 
of the lack of data showing efficacy in patients 
with reflux-related chronic cough.
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Graves’ Disease
To the Editor: We wish to clarify some state-
ments made by Smith and Hegedüs (Oct. 20 is-
sue)1 regarding the serologic diagnosis of Graves’ 
disease and the role of autoantibodies in relation 
to the thyrotropin receptor. The guidelines on hy-
perthyroidism from the American Thyroid Associa-
tion2 strongly recommend measurement of thyro-
tropin-receptor antibodies for accurate and early 
diagnosis as well as management of Graves’ dis-
ease. Functional stimulating thyrotropin-recep-
tor antibodies are causative factors in the hyper-
thyroidism and the extrathyroidal manifestations 
of Graves’ disease, and these antibodies can be 
sensitively and exclusively measured with vali-
dated bioassays that are available worldwide.2 In 
particular, the analytical performance and clini-
cal utility of a stimulatory thyrotropin-receptor 
bioassay in patients with Graves’ disease have been 
demonstrated.3 In addition, a multicenter trial con-
firmed the very high specificity, sensitivity, and 
positive and negative predictive values of this 
tool for the diagnosis of Graves’ disease in chil-
dren.4 Finally, the incorporation and early use of 
stimulating thyrotropin-receptor antibodies in 
current diagnostic algorithms have been shown to 
shorten the time to the diagnosis of Graves’ dis-
ease by 46% and to achieve a cost savings of 47%.5
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To the Editor: In the review of Graves’ disease 
by Smith and Hegedüs, we found that the follow-
ing sentence — “therapy with alemtuzumab, a 
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CD52-targeting monoclonal antibody, can induce 
Graves’ disease” — was too short a summary of 
the issues they raised. Coles et al.1 reported the 
frequent occurrence of Graves’ disease months 
after the cessation of anti-CD52 treatment dur-
ing immune recovery in patients who had under-
gone a durable and profound depletion of T lym-
phocytes, an observation that allowed an interesting 
comparison with studies of lymphopenia-induced 
organ-specific autoimmunity in animals.
We2,3 and others4 have described the occur-
rence of Graves’ disease during immune resto-
ration in severely immunodepressed patients 
infected with the human immunodeficiency 
virus (HIV) who were receiving antiretroviral 
therapy. In these patients, thyroid autoimmu-
nity has been linked to the quantitative recov-
ery of naive CD4+ T cells that were recent thy-
mic emigrants.4
These observations define a specific context 
in which Graves’ disease can occur: lymphopoi-
esis–thymopoiesis after prolonged T-cell deple-
tion, probably leading to errors in the recogni-
tion of self versus nonself by new T cells. We 
believe this phenomenon sheds an interesting 
light on the pathogenesis of Graves’ disease and 
is worthy of attention.
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The authors reply: In our article, we needed to 
determine which of the issues related to Graves’ 
disease should be covered and how to apportion 
our allotted space. In response to the comments 
of Kahaly and Olivio: we maintain that thyrotro-
pin-receptor antibody assays are not always nec-
essary for making the correct diagnosis of 
Graves’ disease. These assays are unavailable in 
some parts of the world, partly because of their 
cost. When used, they provide a reliably accurate 
diagnosis. When the diagnosis is in doubt and 
the assays are available, they should be used. We 
would add that although there is overwhelming 
evidence that anti-thyrotropin–receptor antibod-
ies underlie the hyperthyroidism in Graves’ dis-
ease, the role of these antibodies in thyroid-asso-
ciated ophthalmopathy is considerably less well 
understood.
We appreciate the point raised by Viard and 
Gilquin regarding the complexities involved in 
the development of Graves’ disease in associa-
tion with the anti-CD52 treatment used in mul-
tiple sclerosis. They point to the clinical setting 
of immune-function restoration after antiretro-
viral therapy in patients with HIV who have severe 
immunodepression. Although both situations 
represent examples of immune reconstitution, it 
remains uncertain whether the underlying mech-
anism is identical. Each scenario represents a 
clinical process that engenders unusual immuno-
logic challenges. In our view, more detailed char-
acterization of these two clinical events is war-
ranted. We agree that these examples of iatrogenic 
Graves’ disease may shed important light on dis-
ease pathogenesis and the roles played by spe-
cific T-cell populations.
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